Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg/5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures

NCT06534502 is registered in ClinicalTrials.gov with Azurity Pharmaceuticals as lead sponsor.

NCT NCT06534502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06534502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg/5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures
Lead sponsor
Azurity Pharmaceuticals
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2027
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsies, partial, epilepsy, seizure disorder, partial, seizure, partial, seizure, partial onset, seizures, seizures, focal